Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kyverna Therapeutics, Inc. Common Stock (KYTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: KYTX (1-star) is a SELL. SELL since 1 days. Profits (9.30%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.3% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 119.72M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.78 - 11.40 | Updated Date 07/2/2025 |
52 Weeks Range 1.78 - 11.40 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.08% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -115994722 | Price to Sales(TTM) - |
Enterprise Value -115994722 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 3341.48 | Enterprise Value to EBITDA - | Shares Outstanding 43218900 | Shares Floating 22191595 |
Shares Outstanding 43218900 | Shares Floating 22191595 | ||
Percent Insiders 12.04 | Percent Institutions 68.49 |
Analyst Ratings
Rating 2 | Target Price 17.2 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kyverna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Founded in 2020, it aims to revolutionize treatment for patients with severe autoimmune conditions.
Core Business Areas
- Cell Therapy Development: Developing engineered T cell therapies to selectively target and eliminate autoreactive B cells, addressing the root cause of autoimmune diseases.
Leadership and Structure
Peter Maag, PhD, is the CEO. The company operates with a structure typical of a biotech firm, focusing on research, clinical development, and strategic partnerships.
Top Products and Market Share
Key Offerings
- KYV-101: KYV-101 is Kyverna's lead asset, a fully human CD19 CAR T-cell therapy being investigated for multiple autoimmune diseases, including lupus nephritis, systemic sclerosis, and myasthenia gravis. Phase 1/2 studies are ongoing. Competitors include companies developing similar CAR-T therapies or alternative treatments for autoimmune diseases, such as GSK (Benlysta for lupus).
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is large and growing, with a significant unmet need for more effective and durable treatments. CAR-T therapy represents a novel approach with potential for long-term remission.
Positioning
Kyverna is positioning itself as a leader in the development of CAR-T therapies for autoimmune diseases, differentiating itself through its fully human CAR-T construct and focus on specific patient populations.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be over $100 billion globally. Kyverna, with its CAR-T approach, is targeting a portion of this market by offering potentially curative treatments. Their positioning focuses on specific niches with high unmet need.
Upturn SWOT Analysis
Strengths
- Novel CAR-T approach for autoimmune diseases
- Fully human CAR-T construct potentially reducing immunogenicity
- Strong management team with experience in cell therapy
- Focus on specific autoimmune indications with high unmet need
Weaknesses
- Early stage of development (clinical trials)
- High manufacturing costs associated with cell therapies
- Potential safety concerns with CAR-T therapies (e.g., cytokine release syndrome)
- Dependence on single lead asset (KYV-101)
Opportunities
- Expanding KYV-101 to additional autoimmune indications
- Securing partnerships with larger pharmaceutical companies
- Advancements in CAR-T manufacturing to reduce costs
- Positive clinical trial data demonstrating efficacy and safety
Threats
- Competition from other companies developing CAR-T therapies or alternative treatments
- Regulatory hurdles and approval delays
- Negative clinical trial results
- Changes in reimbursement policies for cell therapies
Competitors and Market Share
Key Competitors
- BMY
- GILD
- JNJ
Competitive Landscape
Kyverna faces competition from established pharmaceutical companies developing traditional autoimmune therapies, as well as other biotech companies developing cell and gene therapies. Kyverna differentiates itself by focusing on a fully human CAR-T construct and specific patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and entry into clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of KYV-101.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials, presenting clinical data at scientific conferences, and securing additional funding.
Summary
Kyverna Therapeutics is a promising clinical-stage biotech company pioneering CAR-T therapies for autoimmune diseases. Its lead asset, KYV-101, shows potential, but the company faces risks associated with clinical development, manufacturing costs, and competition. Successful clinical trials and strategic partnerships are crucial for its future growth. Investors should closely monitor trial results and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kyverna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2024-02-08 | CEO & Director Mr. Warner Biddle | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://kyvernatx.com |
Full time employees 119 | Website https://kyvernatx.com | ||
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.